Claudia Manzoni

List of Publications by Year in Descending Order

61 papers	6,914 citations	26 h-index	65 g-index
65 ext. papers	8,459 ext. citations	7.5 avg, IF	5.14 L-index

#	Paper	IF	Citations
61	The Roc domain of LRRK2 as a hub for protein-protein interactions: a focus on PAK6 and its impact on RAB phosphorylation.. *Brain Research*, **2022**, 1778, 147781	3.7	1
60	Protein interaction network analysis reveals genetic enrichment of immune system genes in frontotemporal dementia.. *Neurobiology of Aging*, **2022**, 116, 67-79	5.6	0
59	Preclinical modeling of chronic inhibition of the Parkinson's disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo. *Molecular Neurodegeneration*, **2021**, 16, 17	19	17
58	Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets. *JAMA Neurology*, **2021**, 78, 464-472	17.2	17
57	MIR-NATs repress MAPT translation and aid proteostasis in neurodegeneration. *Nature*, **2021**, 594, 117-123	50.4	6
56	Integrating protein networks and machine learning for disease stratification in the Hereditary Spastic Paraplegias. *IScience*, **2021**, 24, 102484	6.1	3
55	An integrated genomic approach to dissect the genetic landscape regulating the cell-to-cell transfer of □synuclein. *Cell Reports*, **2021**, 35, 109189	10.6	3
54	Advances in protein-protein interaction network analysis for Parkinson's disease. *Neurobiology of Disease*, **2021**, 155, 105395	7.5	4
53	Mendelian and Sporadic FTD: Disease Risk and Avenues from Genetics to Disease Pathways Through In Silico Modelling. *Advances in Experimental Medicine and Biology*, **2021**, 1281, 283-296	3.6	1
52	SLITRK2, an X-linked modifier of the age at onset in C9orf72 frontotemporal lobar degeneration. *Brain*, **2021**, 144, 2798-2811	11.2	2
51	Exploration of the endo-lysosomal pathway genes in frontotemporal dementia: The use of protein-protein interaction networks to prioritize rare-variant association analysis results. *Alzheimer's and Dementia*, **2020**, 16, e043624	1.2	
50	PINOT: an intuitive resource for integrating protein-protein interactions. *Cell Communication and Signaling*, **2020**, 18, 92	7.5	8
49	Network Analysis for Complex Neurodegenerative Diseases. *Current Genetic Medicine Reports*, **2020**, 8, 17-25	2.2	6
48	Leucine-rich repeat kinase 2 and lysosomal dyshomeostasis in Parkinson disease. *Journal of Neurochemistry*, **2020**, 152, 273-283	6	8
47	, age at onset, and ancestry help discriminate behavioral from language variants in FTLD cohorts. *Neurology*, **2020**, 95, e3288-e3302	6.5	5
46	Genetic variation across RNA metabolism and cell death gene networks is implicated in the semantic variant of primary progressive aphasia. *Scientific Reports*, **2019**, 9, 10854	4.9	5
45	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet Neurology, The*, **2019**, 18, 1091-1102	24.1	562

44	Genetics and molecular mechanisms of frontotemporal lobar degeneration: an update and future avenues. *Neurobiology of Aging*, **2019**, 78, 98-110	5.6	31
43	Comparative Protein Interaction Network Analysis Identifies Shared and Distinct Functions for the Human ROCO Proteins. *Proteomics*, **2018**, 18, e1700444	4.8	23
42	The LRRK2 signalling system. *Cell and Tissue Research*, **2018**, 373, 39-50	4.2	18
41	mTOR independent alteration in ULK1 Ser758 phosphorylation following chronic LRRK2 kinase inhibition. *Bioscience Reports*, **2018**, 38,	4.1	12
40	Genome, transcriptome and proteome: the rise of omics data and their integration in biomedical sciences. *Briefings in Bioinformatics*, **2018**, 19, 286-302	13.4	293
39	Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson's disease brains with Lewy body pathology. *Brain Research*, **2018**, 1701, 75-84	3.7	20
38	Measuring Lactase Enzymatic Activity in the Teaching Lab. *Journal of Visualized Experiments*, **2018**,	1.6	2
37	Genetic Risk Factors for Sporadic Frontotemporal Dementia **2018**, 147-186		1
36	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. *Brain*, **2018**, 141, 2895-2907	11.2	25
35	Protein network analysis reveals selectively vulnerable regions and biological processes in FTD. *Neurology: Genetics*, **2018**, 4, e266	3.8	7
34	Stratification of candidate genes for Parkinson's disease using weighted protein-protein interaction network analysis. *BMC Genomics*, **2018**, 19, 452	4.5	17
33	Tau Mutations Serve as a Novel Risk Factor for Cancer. *Cancer Research*, **2018**, 78, 3731-3739	10.1	17
32	Weighted Protein Interaction Network Analysis of Frontotemporal Dementia. *Journal of Proteome Research*, **2017**, 16, 999-1013	5.6	28
31	The LRRK2-macroautophagy axis and its relevance to Parkinson's disease. *Biochemical Society Transactions*, **2017**, 45, 155-162	5.1	48
30	LRRK2 and Autophagy. *Advances in Neurobiology*, **2017**, 14, 89-105	2.1	38
29	[O2□3□2]: PROTEIN NETWORK ANALYSIS TO PRIORITIZE CANDIDATE GENES AND PATHWAYS FOR SPORADIC DISEASE: A COMPARISON BETWEEN FRONTOTEMPORAL DEMENTIA AND PARKINSON's DISEASE **2017**, 13, P555		1
28	Genetic and phenotypic characterization of complex hereditary spastic paraplegia. *Brain*, **2016**, 139, 1904-18	11.8	123
27	mTOR independent regulation of macroautophagy by Leucine Rich Repeat Kinase 2 via Beclin-1. *Scientific Reports*, **2016**, 6, 35106	4.9	54

26	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*, **2016**, 12, 1-222	10.2	3838
25	Cellular processes associated with LRRK2 function and dysfunction. *FEBS Journal*, **2015**, 282, 2806-26	5.7	101
24	Computational analysis of the LRRK2 interactome. *PeerJ*, **2015**, 3, e778	3.1	38
23	GTP binding controls complex formation by the human ROCO protein MASL1. *FEBS Journal*, **2014**, 281, 261-74	5.7	12
22	Rare variants in LRRK1 and Parkinson's disease. *Neurogenetics*, **2014**, 15, 49-57	3	13
21	Inhibition of LRRK2 kinase activity stimulates macroautophagy. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2013**, 1833, 2900-2910	4.9	109
20	Pathogenic Parkinson's disease mutations across the functional domains of LRRK2 alter the autophagic/lysosomal response to starvation. *Biochemical and Biophysical Research Communications* , **2013**, 441, 862-6	3.4	66
19	Divergent □-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases. *Neurobiology of Disease*, **2013**, 58, 183-90	7.5	34
18	Dysfunction of the autophagy/lysosomal degradation pathway is a shared feature of the genetic synucleinopathies. *FASEB Journal*, **2013**, 27, 3424-9	0.9	55
17	LRRK2 and autophagy: a common pathway for disease. *Biochemical Society Transactions*, **2012**, 40, 1147-51	5.1	19
16	LRRK2 and human disease: a complicated question or a question of complexes?. *Science Signaling*, **2012**, 5, pe2	8.8	54
15	GTP binding and intramolecular regulation by the ROC domain of Death Associated Protein Kinase 1. *Scientific Reports*, **2012**, 2, 695	4.9	10
14	Tetracycline prevents A□ oligomer toxicity through an atypical supramolecular interaction. *Organic and Biomolecular Chemistry*, **2011**, 9, 463-72	3.9	45
13	Pathogenic LRRK2 mutations do not alter gene expression in cell model systems or human brain tissue. *PLoS ONE*, **2011**, 6, e22489	3.7	27
12	The molecular assembly of amyloid a□ controls its neurotoxicity and binding to cellular proteins. *PLoS ONE*, **2011**, 6, e24909	3.7	35
11	LRRK2: a problem lurking in vesicle trafficking?. *Journal of Neuroscience*, **2011**, 31, 9787-8	6.6	8
10	Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 2295-300	11.5	371
9	The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by alpha-synuclein or amyloid-beta (1-42) peptide. *Journal of Neurochemistry*, **2009**, 110, 1445-56	6	209

8	A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. *Science*, **2009**, 323, 1473-7	33.3	306
7	Overcoming synthetic Abeta peptide aging: a new approach to an age-old problem. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2009**, 16, 71-80	2.7	33
6	Conformational plasticity of the Gerstmann-Sträussler-Scheinker disease peptide as indicated by its multiple aggregation pathways. *Journal of Molecular Biology*, **2008**, 381, 1349-61	6.5	53
5	Neurotoxic and gliotrophic activity of a synthetic peptide homologous to Gerstmann-Sträussler-Scheinker disease amyloid protein. *Journal of Neuroscience*, **2007**, 27, 1576-83	6.6	33
4	Gerstmann-Sträussler-Scheinker disease amyloid protein polymerizes according to the "dock-and-lock" model. *Journal of Biological Chemistry*, **2006**, 281, 843-9	5.4	31
3	Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson's disease at Chr16q11.2 and on the MAPT H1 allele		2
2	PKA-mediated phosphorylation of SPG11/spatacsin regulates binding with a subset of 14-3-3 proteins		1
1	Integration of eQTL and Parkinson's disease GWAS data implicates 11 disease genes		4